Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 292,400 shares, a decline of 44.9% from the December 31st total of 530,600 shares. Based on an average trading volume of 3,010,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 4.7% of the company’s shares are sold short.
Biofrontera Price Performance
NASDAQ:BFRI opened at $1.06 on Wednesday. The business’s fifty day moving average price is $1.04 and its 200 day moving average price is $1.06. Biofrontera has a 1-year low of $0.61 and a 1-year high of $2.43.
Analyst Ratings Changes
Separately, Benchmark reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Biofrontera in a research note on Friday, November 15th.
Biofrontera Company Profile
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
See Also
- Five stocks we like better than Biofrontera
- How to Calculate Inflation Rate
- 3 Steel Stocks Soaring After Tariff Announcements
- How to Invest in Insurance Companies: A Guide
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- What is a SEC Filing?
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
